Literature DB >> 9527303

Trials which randomize practices II: sample size.

S M Kerry1, J M Bland.   

Abstract

BACKGROUND: When practices are randomized in a trial and observations are made on the patients to assess the relative effectiveness of the different interventions, sample size calculations need to estimate the number of practices required, not just the total number of patients.
OBJECTIVE: Our aims were to introduce the methodology for appropriate sample size calculation and discuss the implications for power.
METHOD: A worked example from general practice is used. DISCUSSION: Designs which randomize practices are less powerful than designs which randomize patients to intervention groups, particularly where a large number of patients is recruited from each practice. Studies which randomize few practices should be avoided if possible, as the loss of power is considerable and simple randomization may not ensure comparability of intervention groups.

Entities:  

Mesh:

Year:  1998        PMID: 9527303     DOI: 10.1093/fampra/15.1.84

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  17 in total

1.  Considerations for the design and analysis of experimental studies in physical activity and exercise promotion: advantages of the randomised controlled trial.

Authors:  S S Tai; S Iliffe
Journal:  Br J Sports Med       Date:  2000-06       Impact factor: 13.800

Review 2.  Considering clustering: a methodological review of clinical decision support system studies.

Authors:  J H Chuang; G Hripcsak; R A Jenders
Journal:  Proc AMIA Symp       Date:  2000

3.  Design and analysis of controlled trials in naturally clustered environments: implications for medical informatics.

Authors:  Jen-Hsiang Chuang; George Hripcsak; Daniel F Heitjan
Journal:  J Am Med Inform Assoc       Date:  2002 May-Jun       Impact factor: 4.497

Review 4.  Design and analysis of group-randomized trials: a review of recent methodological developments.

Authors:  David M Murray; Sherri P Varnell; Jonathan L Blitstein
Journal:  Am J Public Health       Date:  2004-03       Impact factor: 9.308

5.  Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial.

Authors:  Andrew C Hayward; Richard Harling; Sally Wetten; Anne M Johnson; Susan Munro; Julia Smedley; Shahed Murad; John M Watson
Journal:  BMJ       Date:  2006-12-01

6.  Lack of benefit of a primary care-based nurse-led education programme for people with osteoarthritis of the knee.

Authors:  Christina R Victor; Eric Triggs; Fiona Ross; Joanne Lord; John S Axford
Journal:  Clin Rheumatol       Date:  2005-06-04       Impact factor: 2.980

7.  Intraclass Correlation Coefficients for Planning Cluster Randomized Trials in Community-Dwelling Older Adults.

Authors:  Subashan Perera; Neelesh K Nadkarni; David Wert; Jessie VanSwearingen; Jennifer S Brach
Journal:  J Aging Health       Date:  2018-12-06

8.  De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.

Authors:  Marc Leone; Carole Bechis; Karine Baumstarck; Jean-Yves Lefrant; Jacques Albanèse; Samir Jaber; Alain Lepape; Jean-Michel Constantin; Laurent Papazian; Nicolas Bruder; Bernard Allaouchiche; Karine Bézulier; François Antonini; Julien Textoris; Claude Martin
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

Review 9.  Internal and external validity of cluster randomised trials: systematic review of recent trials.

Authors:  Sandra Eldridge; Deborah Ashby; Catherine Bennett; Melanie Wakelin; Gene Feder
Journal:  BMJ       Date:  2008-03-25

10.  Electronic medical record-assisted design of a cluster-randomized trial to improve diabetes care and outcomes.

Authors:  Thomas E Love; Randall D Cebul; Douglas Einstadter; Anil K Jain; Holly Miller; C Martin Harris; Peter J Greco; Scott S Husak; Neal V Dawson
Journal:  J Gen Intern Med       Date:  2008-04       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.